D-amino acids and retro-inverso peptides
D-amino acids are mirror images of the natural L-forms. This guide explains chirality in peptides, why D-substitutions resist proteases, how retro-inverso peptides such as FOXO4-DRI are designed, and how D-content is analyzed.
Chirality in amino acids
Every standard amino acid except glycine has a chiral alpha carbon carrying four different groups, so it exists in two mirror-image forms that cannot be superimposed. These are labeled L and D by convention. Proteins and ribosomally made peptides in living organisms use L-amino acids almost exclusively, and the enzymes that process them, including proteases, are themselves built from L-amino acids and are stereoselective.
D-amino acids do occur in nature, for example in bacterial cell walls, in some peptides from amphibian skin and cone snails, and as free D-serine in the nervous system. In synthetic peptides they are introduced deliberately to change shape or stability. Achiral residues such as glycine and Aib have no D-form. For notation, see peptide nomenclature and modifications.
Why D-substitutions are used
A D-residue changes the local backbone geometry and the direction in which its side chain points. In many peptides a single D-substitution is used to stabilize a turn or a particular conformation that the receptor recognizes. It also tends to make the adjacent peptide bonds poor substrates for proteases, because the enzyme's active site is shaped for L-residues.
Approved and research peptides illustrate the approach. GnRH analogues such as triptorelin replace glycine at position 6 with a D-amino acid, which favors a turn conformation and slows enzymatic breakdown. Melanocortin ligands including melanotan II and setmelanotide contain D-phenylalanine in the core motif, which was found to increase potency in early structure-activity work.
D-residues in growth hormone secretagogues
Several synthetic ghrelin-receptor agonists are short peptides that rely heavily on non-natural residues. Ipamorelin is a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, combining an achiral Aib at the N-terminus, two D-aromatic residues in the middle and a C-terminal amide. GHRP-6 and GHRP-2 likewise contain D-residues.
In these molecules the D-residues are part of the pharmacophore rather than simple stabilizing substitutions, so replacing them with L-forms would produce different compounds with different activity. For analytical purposes, an all-L version of such a sequence has the same mass and may be hard to separate by standard HPLC, which is why stereochemical identity needs dedicated methods.
All-D and retro-inverso peptides
An all-D peptide, the exact mirror image of an L-peptide, has the same sequence written with D-residues. It is highly resistant to proteases but generally does not bind a chiral target in the same way, because the side chains and backbone are mirrored. Mirror-image phage display exploits this by selecting L-peptides against a D-version of the target, then synthesizing the D-peptide to bind the natural L-target.
A retro-inverso peptide reverses the sequence order and uses D-residues throughout. The result is a molecule whose side chains have a spatial arrangement broadly similar to the parent L-peptide, while the backbone amide bonds run in the opposite direction. In principle this preserves side-chain presentation while providing protease resistance. In practice the mimicry is imperfect, because backbone hydrogen-bonding patterns and terminal groups differ, and retro-inverso analogues have shown variable activity across published studies.
Whether a retro-inverso analogue retains activity seems to depend on how much the parent peptide relies on backbone interactions. Peptides that bind mainly through side-chain contacts in an extended conformation are better candidates than those whose activity depends on a helix or specific backbone hydrogen bonds. Terminal groups pose a further problem, since reversing the sequence swaps the positions of the free amine and carboxyl, and designers sometimes add or modify terminal groups to compensate. Each retro-inverso peptide therefore has to be evaluated experimentally rather than assumed to mimic its parent.
FOXO4-DRI as an example
FOXO4-DRI is a D-retro-inverso peptide derived from a region of the FOXO4 transcription factor and designed to interfere with the interaction between FOXO4 and p53. It was reported in a mouse study to induce apoptosis selectively in senescent cells and has since been used in other cell and animal experiments. Human evidence is absent.
Its retro-inverso design means the written sequence runs opposite to the native FOXO4 segment and every chiral residue is D. Identity testing by mass spectrometry confirms composition but cannot distinguish it from an all-L or forward-sequence version with the same residues, so documentation should state the stereochemistry and sequence orientation explicitly. FOXO4-DRI also includes a cell-penetrating segment, which adds basic residues and raises its counter-ion content.
As with other peptides studied mainly in one or a few laboratories, the published findings for FOXO4-DRI are best read with attention to model, material characterization and replication; see how to read preclinical research. It is not approved for any use.
Analyzing D-amino acid content
Mass spectrometry measures mass, and an L-residue and its D-isomer have identical masses. Standard reversed-phase HPLC may separate diastereomers, peptides differing in the configuration of one or a few residues, but often only partially. Stereochemical identity therefore needs complementary methods.
- Chiral amino acid analysis: hydrolysis followed by derivatization with a chiral reagent, such as Marfey's reagent, or separation on a chiral column, to measure the L and D content of each residue.
- Optimized HPLC: shallow gradients or alternative column chemistries to resolve diastereomeric impurities from racemization.
- Comparison with a reference standard: co-injection with authentic material.
- Spectroscopy: circular dichroism distinguishes mirror-image peptides, which give opposite spectra.
Racemization as an impurity
Racemization, the unintended conversion of an L-residue to D or vice versa, can occur during synthesis, particularly at histidine and cysteine and during activation of certain residues, and through aspartimide formation in storage. The resulting diastereomers are impurities with the correct mass that may co-elute with the main product, so a high HPLC purity does not exclude them.
For peptides where stereochemistry is central to activity, a certificate of analysis that includes chiral purity data, or at least a validated HPLC method shown to separate known diastereomers, provides stronger assurance. See solid-phase peptide synthesis and how to read a COA.
Frequently asked questions
Why are D-amino acid peptides more stable?
Proteases are built from L-amino acids and have active sites shaped to recognize L-residues. Peptide bonds next to D-residues fit poorly and are cleaved slowly or not at all. A single D-substitution can protect a vulnerable site, while all-D peptides are highly resistant to most common proteases.
What does retro-inverso mean?
A retro-inverso peptide has its sequence reversed (retro) and every chiral residue converted to the D-form (inverso). The combination places side chains in roughly the same spatial arrangement as the parent L-peptide while reversing the backbone direction, aiming to retain recognition while resisting proteases. The mimicry is approximate, and activity varies between examples.
Can mass spectrometry detect D-amino acids?
Not directly. L- and D-isomers have identical masses, so a standard mass spectrum cannot tell them apart. Stereochemistry is assessed by chiral amino acid analysis after hydrolysis, by HPLC methods able to separate diastereomers, by comparison with a reference standard, or by circular dichroism for mirror-image peptides.
Compounds mentioned
Cite this page